AI Mines Clinical Data for Thyroid Cancer Therapeutic Targets

The Helomics division of Predictive Oncology and Interpace Diagnostics Group Inc. have announced a cooperative research agreement. Helomics has developed an AI bioinformatic platform, known as “D-CHIP,” while Interpace has collected an impressive cache of clinical data from next-generation sequencing (NGS) and microRNA testing of thyroid tumor samples from its combination ThyGeNEXT panel and ThyroMIR classifier. By analyzing the Interpace datasets on the D-CHIP platform, Helomics and Interpace plan to improve diagnosis of thyroid cancer and identify druggable targets. The ThyGeNEXT and ThyraMIR combination testing platform for genetic alterations and micro RNA expression detects markers for specific types of thyroid cancer. Traditionally, thyroid cancer was diagnosed by cytology reads from fine needle aspiration (FNA) biopsy of suspicious thyroid nodules. However, up to 30% of FNA samples are cytologically indeterminate. Furthermore, thyroid tumors range from relatively benign and slow growing to aggressive tumors with a high likelihood of metastasis. Interpace has selected markers for its panels that are specific for individual subtypes of thyroid cancer. “We want to choose markers that matter,” Alidad Mireskandari, PhD, vice president of business development of Interpace, told MD+DI. “TERT and ALK,” he pointed out, “are marker...
Source: MDDI - Category: Medical Devices Authors: Tags: Software Source Type: news